X0303 4 2010-03-04 0 0001401923 MAP Pharmaceuticals, Inc. MAPP 0001253598 SFM PARTICIPATION LP 888 SEVENTH AVENUE 31ST FLOOR NEW YORK NY 10106 0 0 1 0 0001237655 SFM AH LLC 888 SEVENTH AVENUE 31ST FLOOR NEW YORK NY 10106 0 0 1 0 Common Stock 2010-03-04 4 S 0 97 14.09 D 2861970 I See Footnotes Common Stock 2010-03-04 4 S 0 677 14.15 D 2861970 I See Footnotes Common Stock 2010-03-04 4 S 0 3061 14.15 D 2861970 I See Footnotes Common Stock 2010-03-05 4 S 0 6524 13.95 D 2829958 I See Footnotes Common Stock 2010-03-05 4 S 0 4616 13.95 D 2829958 I See Footnotes Common Stock 2010-03-05 4 S 0 20872 13.95 D 2829958 I See Footnotes The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.00 to $14.23. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"), Perseus-Soros Partners, LLC ("Perseus-Soros Partners"), the general partner of Perseus-Soros, SFM Participation, L.P ("SFM Participation"), a managing member of Perseus-Soros Partners, and Biotech Management Partners, LLC ("Biotech Management Partners"). SFM Participation is a managing member of Biotech Management Partners. SFM AH, LLC ("SFM AH"), is the general partner of SFM Participation. Represents 97 shares of the Issuer's Common Stock sold by SFM Participation. After the sale SFM Participation owns directly 10,313 shares of the Issuer's Common Stock. Represents 677 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale Perseus-Soros Partners owns directly 4,616 shares of the Issuer's Common Stock. Represents 3,061 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale Biotech Management Partners owns directly 20,872 shares of the Issuer's Common Stock. The price shown in Column 4 is a weighted average sale price. The price range for the sales is $13.70 to $14.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Represents 6,524 shares of the Issuer's Common Stock sold by SFM Participation. After the sale SFM Participation owns directly 3,789 shares of the Issuer's Common Stock. Represents 4,616 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale Perseus-Soros Partners directly owns no shares of the Issuer's Common Stock. Represents 20,872 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale Biotech Management Partners directly owns no shares of the Issuer's Common Stock. (10) Mr. Schoenfarber is signing in his capacity as Ass't. General Counsel of Soros Fund Management LLC, as Managing Member of SFM AH LLC, as General Partner of SFM Participation, L.P.(11) Mr. Schoenfarber is signing in his capacity as Ass't. General Counsel of Soros Fund Management LLC, as Managing Member of SFM AH LLC. /s/ Jay Schoenfarber (10) 2010-03-08 /s/ Jay Schoenfarber (11) 2010-03-08